Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

BMJ Open

Volumn 3, Issue 6, 2013, Pages

  Guzman, Juan D ^a,b   Evangelopoulos, Dimitrios ^a,c   Gupta, Antima ^a   Birchall, Kristian ^d   Mwaigwisya, Solomon ^c   Saxty, Barbara ^d   McHugh, Timothy D ^c   Gibbons, Simon ^b   Malkinson, John ^b   Bhakta, Sanjib ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; CARPROFEN; ETHAMBUTOL; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOPROFEN; INITIATION FACTOR; ISONIAZID; KETOPROFEN; LOXOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; RIFAMPICIN;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; VALIDATION STUDY;

EID: 84879926690     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002672     Document Type: Article

References (48)

1. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43.
2. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-19.
3. Bhakta S, Besra GS, Upton AM, et al. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J Exp Med 2004;199:1191-9. (Pubitemid 38620256)
4. Evangelopoulos D, Bhakta S. Rapid methods for testing inhibitors of mycobacterial growth. Methods Mol Biol 2010;642:193-201.
5. Guzman JD, Gupta A, Evangelopoulos D, et al. Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65:2101-7.
6. Anderton MC, Bhakta S, Besra GS, et al. Characterization of the putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG. Mol Microbiol 2006;59:181-92.
7. Madikane VE, Bhakta S, Russell AJ, et al. Inhibition of mycobacterial arylamine N-acetyltransferase contributes to anti-mycobacterial activity of Warburgia salutaris . Bioorg Med Chem 2007;15:3579-86. (Pubitemid 46546632)
8. Van Klingeren B, Dessens-Kroon M, Van der Laan T, et al. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol 2007;45:2662-8. (Pubitemid 47295501)
9. Nzila A, Ma Z, Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem 2011;3:1413-26.
10. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645-6. (Pubitemid 47236844)
11. Amaral L, Boeree MJ, Gillespie SH, et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Ag 2010;35:524-6.
12. Van Soolingen D, Hernandez-Pando R, Orozco H, et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS ONE 2010;5:e12640.
13. Horita Y, Takii T, Yagi T, et al. Anti-tubercular activity of disulfiram, an anti-alcoholism drug, against multi-drug and extensively drug-resistant Mycobacterium tuberculosis isolates. Antimicrob Ag Chemother 2012;56:4140-5.
14. Gold B, Pingle M, Brickner SJ, et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. PNAS 2012;109:16004-11.
15. Sanyal AK, Roy D, Chowdhury B, et al . Ibuprofen, a unique anti-inflammatory compound with antifungal activity against dermatophytes. Let Appl Microbiol 1993;17:109-11. (Pubitemid 23278205)
16. Elvers KT, Wright SJL. Antibacterial activity of the anti-inflammatory compound ibuprofen. Let Appl Microbiol 1995;20:82-4.
17. Byrne ST, Denkin SM, Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother 2007;59:313-16. (Pubitemid 47072074)
18. Pearce BC, Sofia MJ, Good AC, et al. An empirical process for the design of high-throughput screening deck filters. J Chem Inf Model 2006;46:1060-8. (Pubitemid 43999150)
19. Gupta A, Bhakta S. An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis. J Antimicrob Chemother 2012;67:1380-91.
20. Bushra R, Aslam N. An overview of clinical pharmacology of Ibuprofen. Oman Med J 2010;25:155-1661.
21. Gasparini L, Ongini E, Wilcock D, et al. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Rev 2005;48:400-8. (Pubitemid 40585770)
22. Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)?: in vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002;63:343-7. (Pubitemid 34169714)
23. Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007;64:1403-18. (Pubitemid 46889230)
24. Lew JM, Kapopoulou A, Jones LM, et al. TubercuList - 10 years after. Tuberculosis 2011;91:1-7.
25. Peng L, Wang B, Ren P. Reduction of MTT by flavonoids in the absence of cells. Colloids Surf B 2005;45:108-11. (Pubitemid 41266927)
26. O'Brien J, Wilson I, Orton T, et al. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Europ J Biochem 2000;267:5421-6.
27. Yao M, Zhou W, Sangha S, et al . Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11:1618-28. (Pubitemid 40315247)
28. Konstan MW, Krenicky JE, Finney MR, et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003;306:1086-91. (Pubitemid 37025317)
29. McElwee NE, Veltri JC, Bradford DC, et al. A prospective, population-based study of acute ibuprofen overdose: complications are rare and routine serum levels not warranted. Ann Emerg Med 1990;19:657-62. (Pubitemid 20180908)
30. Hall AH, Smolinske SC, Conrad FL, et al. Ibuprofen overdose: 126 cases. Ann Emerg Med 1986;15:1308-13. (Pubitemid 17184491)
31. Graham GG, Williams KM. Metabolism and pharmacokinetics of ibuprofen. In: Rainsford KD, ed. Aspirin and related drugs. CRC Press, 2004.
32. Stratman NC, Carter DB, Sethy VH. Ibuprofen: effect on inducible nitric oxide synthase. Mol Brain Res 1997;50:107-12. (Pubitemid 27488896)
33. Stuhlmeier KM, Li H, Kao JJ. Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol 1999;57:313-20. (Pubitemid 29056210)
34. Arriaga AK, Orozco EH, Aguilar LD, et al. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002;128:229-37. (Pubitemid 34534035)
35. Kuo HP, Wang CH, Huang KS, et al. Nitric oxide modulates interleukin-1 β and tumor necrosis factor-α synthesis by alveolar macrophages in pulmonary tuberculosis. Am J Respir Crit Care Med 2000;161:192-9. (Pubitemid 30055925)
36. Fox SM, Johnston SA. Use of carprofen for the treatment of pain and inflammation in dogs. J Am Vet Med Assoc 1997;210:1493-8. (Pubitemid 27204780)
37. Taylor PM, Delatour P, Landont FM, et al. Pharmacodynamics and enantioselective pharmacokinetics of carprofen in the cat. Res Vet Sci 1996;60:144-51. (Pubitemid 26074198)
38. McKellar QA, Delatour P, Lees P. Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. J Vet Pharmacol Ther 1994;17:447-54.
39. Spahn H, Spahn I, Benet LZ. Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study. Clin Pharm Ther 1989;45:500-5. (Pubitemid 19155028)
40. EAEMP. Carprofen summary report. Committee for veterinary medicinal products: The European Agency for the Evaluation of Medicinal Products, 1995.
41. Xie G, Sun Y, Nie T, et al. Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 2011;337:876-86.
42. Mirshahi F, Fowler G, Patel A, et al. Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity. J Clin Pathol 1998;51:220-4.
43. Deb C, Lee CM, Dubey VS, et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE 2009;4:e6077.
44. Bartek IL, Rutherford R, Gruppo V, et al. The DosR regulon of M. tuberculosis and antibacterial tolerance. Tuberculosis 2009;89:310-16.
45. Sriram D, Yogeeswari P, Dhakla P, et al. 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant Mycobacterium species. Bioorg Med Chem Let 2009;19:1152-4.
46. Guenneugues M, Caserta E, Brandi L, et al. Mapping the fMet-tRNAfMet binding site of initiation factor IF2. EMBO J 2000;19:5233-40.
47. Yuan Y, Crane DD, Barry CE. Stationary phase-associated protein expression in Mycobacterium tuberculosis : function of the mycobacterial alpha-crystallin homolog. J Bacteriol 1996;178:4484-92. (Pubitemid 26262233)
48. Hu YM, Butcher PD, Sole K, et al. Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Let 1998;158:139-45. (Pubitemid 28088115)